Steatosis and chronic hepatitis C infection: Mechanisms and significance

Clinical Gastroenterology and Hepatology

Volumn 3, Issue SUPPL. 2, 2005, Pages

  Harrison, Stephen A ^a  

^a BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; FATTY LIVER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOST PATHOGEN INTERACTION; HUMAN; INSULIN RESISTANCE; LIVER FIBROSIS; METABOLISM; NONHUMAN; PATHOPHYSIOLOGY;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; FATTY LIVER; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; RISK FACTORS;

EID: 26444596150     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(05)00706-8     Document Type: Conference Paper

References (40)

1. M.P. Manns, J.G. McHutchison, S.C. Gordon Peginterferon alfa-2b in combination with ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C results of a randomized trial Lancet 358 2001 958 965
2. M.W. Fried, M.L. Shiffman, K.R. Reddy Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
3. S.J. Hadziyannis, H. Sette, T.R. Morgan Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C Ann Intern Med 140 2004 346 355
4. A. Lonardo, L.E. Adinolfi, P. Loria Steatosis and hepatitis C mechanisms and significance for hepatic and extrahepatic disease Gastroenterology 126 2004 586 597
5. L. Castera, P. Chouteau, C. Hezode Hepatitis C virus-induced hepatocellular steatosis Am J Gastroenterol 100 2005 711 715
6. S.T. Shi, S.J. Polyak, H. Tu Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins Virology 292 2002 198 210
7. A. Sabile, G. Perlemuter, F. Bono Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates Hepatology 30 1999 1064 1076
8. G. Perlemuter, A. Sabile, P. Letteron Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion a model of viral-related steatosis FASEB J 16 2002 185 194
9. L. Serfaty, T. Andreani, P. Giral Hepatitis C virus induced hypobetalipoproteinemia a possible mechanism for steatosis in chronic hepatitis C J Hepatol 34 2001 428 434
10. A. Dev, K. Patel, J.G. McHutchinson Hepatitis C and steatosis Clin Liver Dis 8 2004 881 892
11. S.A. Harrison, B.A. Neuschwander-Tetri Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis Clin Liver Dis 8 2004 861 879
12. E.M. Brunt, S. Ramrakhiani, B.G. Cordes Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease Mod Pathol 16 2003 49 56
13. J.P. Ong, Z.M. Younossi, C. Speer Chronic hepatitis C and superimposed nonalcoholic fatty liver disease Liver 21 2001 266 271
14. S. Ramesh, A.J. Sanyal Hepatitis C and nonalcoholic fatty liver disease Semin Liver Dis 24 2004 399 413
15. T. Poynard, V. Ratziu, J.G. McHutchison Effect of treatment with peginterferon or interferon alpha-2b and ribavirin on steatosis in patients infected with hepatitis C Hepatology 38 2003 75 85
16. A.J. Sanyal, M.J. Contos, R.K. Sterling Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome Am J Gastroenterol 98 2003 2064 2071
17. K.C. Thomopoulos, G.J. Theocharis, A.C. Tsamantas Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C Eur J Gastroenterol Hepatol 17 2005 149 153
18. H.M. Patton, K. Patel, C. Behling The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients J Hepatol 40 2004 484 490
19. S.A. Harrison, E.M. Brunt, D.A. Oliver Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C Clin Gastroenterol Hepatol 3 2005 604 609
20. L. Fartoux, O. Chazouilleres, D. Wendum Impact of steatosis on progression of fibrosis in patients with mild hepatitis C Hepatology 41 2005 82 87
21. K.-Q. Hu, N.L. Kyulo, E. Esrailian Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C a retrospective study on a large cohort of patients in the United States J Hepatol 40 2004 147 154
22. V. Ratziu, J.-B. Trabut, T. Poynard Fat, diabetes, and liver injury in chronic hepatitis C Curr Gastro Rep 6 2004 22 29
23. L.E. Adinolfi, R. Utili, A. Andreana Serum HCV-RNA levels correlate with histologic liver damage and concur with steatosis in progression of chronic hepatitis C Dig Dis Sci 46 2001 1677 1683
24. M.J. Walsh, D.M. Vanags, A.D. Clouston Steatosis and liver cell apoptosis in chronic hepatitis C a mechanism for increased liver injury Hepatology 39 2004 1230 1238
25. L. Castera, C. Hezode, F. Roudot-Thoroaval Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies Gut 52 2003 288 292
26. I.J. Hickman, E.E. Powell, J.B. Prins In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis implications for therapy J Hepatol 39 2003 1042 1048
27. V. Ratziu, M. Munteanu, F. Charlotte Fibrogenic impact of high serum glucose in chronic hepatitis C J Hepatol 39 2003 1049 1055
28. J.M. Hui, A. Sud, G.C. Farrell Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression Gastroenterology 125 2003 1695 1704
29. I.J. Hickman, A.D. Clouston, G.A. Macdonald Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C Gut 51 2002 89 94
30. A.E. Feldstein, A. Canbay, P. Angulo Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis Gastroenterology 125 2003 437 443
31. N.K. Saxena, K. Ikeda, D.C. Rockey Leptin in hepatic fibrosis evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice Hepatology 35 2002 762 771
32. M. Romero-Gomez, V.M. Castellano-Megias, L. Grande Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C Am J Gastroenterol 98 2003 1135 1141
33. A.J. McCullough Obesity and its nurturing effect on hepatitis C Hepatology 38 2003 557 559
34. M. Romero-Gomez, M. Del Mar Viloria, R.J. Andrade Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients Gastroenterology 128 2005 636 641
35. A. Widjaja, H. Wedemeyer, H.L. Tillmann Hepatitis C and the leptin system bound leptin levels are elevated in patients with hepatitis C and decrease during antiviral therapy Scand J Gastroenterol 36 2001 426 431
36. G.M. Lord, G. Matarese, J.K. Howard Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression Nature 394 1998 897 901
37. B.L. Bressler, M. Guindi, G. Tomlinson High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C Hepatology 38 2003 639 644
38. G. Taliani, F. Duca, R. Lecce Hepatic lidocaine metabolism in chronic hepatitis C virus hepatitis with or without steatosis Hepatology 21 1995 1760 1761
39. R. Bruno, P. Sacchi, V. Ciappina Pharmacokinetics of peginterferon alpha 2° (40 KD, Pegasys) compared to peginterferon alpha 2b (12 KD, Peginteron) in naive patients with chronic hepatitis C (CHC) (abstr) J Hepatol 38 Suppl 2 2003 129 130
40. N.P. Lam, D. Pitrak, R. Speralakis Effect of obesity on pharmacokinetics and biologic effect of interferon-α in hepatitis C Dig Dis Sci 42 1997 178 185